BERLIN (dpa-AFX) – The radiation and medical technology group Eckert & Ziegler ended the past year better than expected. According to preliminary figures, a surplus of almost 30 million euros was achieved in 2022 with sales of around 225 million euros, as the company, which is listed in the small value index SDax, announced on Tuesday in Berlin. This means that revenue and earnings are expected to be around ten percent higher than management expected, it said.
Eckert & Ziegler benefited last year from demand from the oil industry and for pharmaceutical radioisotopes. However, the group had to lower its profit forecast for 2022 in July, partly because of a slowdown in the economy. The company had recently forecast sales of around 200 million euros and a surplus of around 27 million euros for the twelve months. Originally, however, the Berliners had assumed a profit of a good 38 million./tav/stk
